NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 106.33 |
| Open | 106.08 |
| Bid | 104.65 x 1400 |
| Ask | 104.72 x 800 |
| Day's Range | 104.19 - 107.30 |
| 52 Week Range | 71.85 - 119.65 |
| Volume | 757,693 |
| Avg. Volume | 942,391 |
| Market Cap | 9.639B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | 475.77 |
| EPS (TTM) | 0.22 |
| Earnings Date | Feb 02, 2020 - Feb 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 27, 1995 |
| 1y Target Est | 121.28 |
- PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
- Zacks
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
- Zacks
Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
- GlobeNewswire
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments.
- PR Newswire
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and clinical development milestones for 2020. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).
- Zacks
AMRX vs. NBIX: Which Stock Is the Better Value Option?
AMRX vs. NBIX: Which Stock Is the Better Value Option?
- PR Newswire
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019 granting Neurocrine Biosciences an option to license ACT-709478, a potent, selective, orally-active, and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The option also includes a research collaboration to discover, identify and develop additional novel T-type calcium channel blockers.
- Zacks
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- PR Newswire
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) on Monday, Jan. 13, 2020, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.
- Simply Wall St.
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair?
In 2008 Kevin Gorman was appointed CEO of Neurocrine Biosciences, Inc. (NASDAQ:NBIX). This analysis aims first to...
- Insider Monkey
How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- Zacks
3 Breakout Stocks of the Last Decade to Consider for 2020
The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Kiplinger
The Top 10 Stocks of the Past Decade
One thing nearly everyone can agree on about the past decade is that it has been very, very good for stock market investors. The Russell 1000 large-company index, which tracks the 1,000 biggest U.S. stocks by market value, has gained roughly 252% since the start of the 2010s, including reinvested dividends.Some stocks have done far better. Microsoft (MSFT) awoke from its long slumber and jumped 545% over the past decade. Dollar General (DG) made a lot of bucks, gaining 632%. And Ulta Beauty (ULTA) has made a lovely 1,325% gain.But those aren't the tippy-top stocks of the Russell 1000. Not even close.Here are the top 10 large-company stocks of the decade, as well as a look at what put them on top of the heap. We chose the Russell 1000 because it offers an even broader look at the stock market than the S&P; 500, but still excludes smaller companies where extremely outsize gains are more common and can more easily come from a single, quick driver. SEE ALSO: The 20 Best Stocks to Buy for 2020
- GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced today that it will provide updates on its partnered epilepsy programs at the American Epilepsy Society (AES) Annual Meeting held in Baltimore, MD.
- Simply Wall St.
With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- Benzinga
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
- GlobeNewswire
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
SAN DIEGO and BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Xenon Pharmaceuticals Inc. (XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosciences gains an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
- PR Newswire
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, demonstrating that treatment with once-daily 40 mg or 80 mg of INGREZZA reduced involuntary movements in adults who had moderate or severe tardive dyskinesia (TD) and clinical diagnoses of schizophrenia, schizoaffective disorder or a mood disorder.
- Thomson Reuters StreetEvents
Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT
Q3 2019 Neurocrine Biosciences Inc Earnings Call
- PR Newswire
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy ...
